PTCL
Oncology · 2016–2026
3decisions
2medicines
1carried consumer input
1individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| romidepsin Treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) following at least one prior systemic therapy. | Mar 2026 | Recommended with restriction | no section in document |
| romidepsin Treatment of relapsed or chemotherapy-refractory peripheral T-cell lymphoma (PTCL) following at least first-line chemotherapy. | Dec 2017 | Deferred | 1 individuals |
| pralatrexate Treatment of relapsed or chemotherapy refractory peripheral T-cell lymphoma (PTCL) in adult patients who have progressed after at least one prior therapy. | Mar 2016 | Not recommended | none received |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.